AGILENT TECHNOLOGIES, INC.
AAPI behind this page
A Q1 2026 request
Playground key active
/api/financials?ticker=A&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 1,798 | 1,681 | +7.0% |
Show Product Lines breakouts |
|||
| Instrumentation | 658 | 625 | +5.3% |
| Non-Instrumentation and Other | 1,140 | 1,056 | +8.0% |
| Product | 1,273 | 1,200 | +6.1% |
| Service Other | 525 | 481 | +9.1% |
Show Business Segments breakouts |
|||
| Agilent CrossLab | 758 | 696 | +8.9% |
| Agilent CrossLab · Americas | 273 | 261 | +4.6% |
| Agilent CrossLab · Asia Pacific | 270 | 247 | +9.3% |
| Agilent CrossLab · Europe | 215 | 188 | +14.4% |
| Applied Markets | 361 | 338 | +6.8% |
| Applied Markets · Americas | 98 | 96 | +2.1% |
| Applied Markets · Asia Pacific | 163 | 157 | +3.8% |
| Applied Markets · Europe | 100 | 85 | +17.6% |
| Life Sciences and Diagnostics Markets | 679 | 647 | +4.9% |
| Life Sciences and Diagnostics Markets · Americas | 307 | 312 | -1.6% |
| Life Sciences and Diagnostics Markets · Asia Pacific | 169 | 145 | +16.6% |
| Life Sciences and Diagnostics Markets · Europe | 203 | 190 | +6.8% |
Show Geography breakouts |
|||
| Americas | 678 | 669 | +1.3% |
| Asia Pacific | 602 | 549 | +9.7% |
| Europe | 518 | 463 | +11.9% |
Show End Markets [Axis] breakouts |
|||
| Academia and Government Market | 130 | 137 | -5.1% |
| Chemicals and Advanced Materials Market | 422 | 379 | +11.3% |
| Diagnostics and Clinical Market | 263 | 240 | +9.6% |
| Environmental and Forensics Market | 177 | 172 | +2.9% |
| Food Market | 166 | 168 | -1.2% |
| Pharmaceutical and Biotechnology Market | 640 | 585 | +9.4% |
| Cost of Revenue | 852 | 782 | +9.0% |
Show Product Lines breakouts |
|||
| Product | 571 | 535 | +6.7% |
| Service Other | 281 | 247 | +13.8% |
Show Business Segments breakouts |
|||
| Agilent CrossLab | 340 | 306 | +11.1% |
| Applied Markets | 157 | 150 | +4.7% |
| Life Sciences and Diagnostics Markets | 336 | 305 | +10.2% |
| Total Costs & Expenses | 1,445 | 1,305 | +10.7% |
| Research & Development | 117 | 113 | +3.5% |
Show Business Segments breakouts |
|||
| Agilent CrossLab | 28 | 26 | +7.7% |
| Applied Markets | 24 | 23 | +4.3% |
| Life Sciences and Diagnostics Markets | 65 | 63 | +3.2% |
| Selling, General & Administrative | 476 | 410 | +16.1% |
Show Business Segments breakouts |
|||
| Agilent CrossLab | 150 | 143 | +4.9% |
| Applied Markets | 87 | 81 | +7.4% |
| Life Sciences and Diagnostics Markets | 169 | 162 | +4.3% |
| Operating Expenses (Q) | — | — | — |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 89 | 46 | +93.5% |
| Operating Income | 353 | 376 | -6.1% |
Show Business Segments breakouts |
|||
| Agilent CrossLab · Operating Segments | 240 | 221 | +8.6% |
| Applied Markets · Operating Segments | 93 | 84 | +10.7% |
| Life Sciences and Diagnostics Markets · Operating Segments | 109 | 117 | -6.8% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 442 | 422 | +4.7% |
| Interest Income | 15 | 15 | 0.0% |
| Other Non-Operating Income (Expense) | 21 | 4 | +425.0% |
| Income Before Taxes | 364 | 367 | -0.8% |
| Income Tax Expense (Benefit) | 59 | 49 | +20.4% |
| Net Income | 305 | 318 | -4.1% |
Show Equity Components breakouts |
|||
| Parent | 305 | 318 | -4.1% |
| Retained Earnings | 305 | 318 | -4.1% |
| Comprehensive Income (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Parent | 347 | 242 | +43.4% |
| EPS (Basic) | 1.08 | 1.12 | -3.6% |
| EPS (Diluted) | 1.07 | 1.11 | -3.6% |
| Wtd Avg Shares (Basic) | 283 | 285 | -0.7% |
| Wtd Avg Shares (Diluted) | 284 | 287 | -1.0% |
| Interest Expense | -25 | -28 | +10.7% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax | -7 | 11 | -163.6% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,758 | — | — |
| Accounts Receivable | 1,521 | — | — |
| Inventory | 1,059 | — | — |
| Other Assets Current | 277 | — | — |
| Total Current Assets | 4,615 | — | — |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,078 | — | — |
| Goodwill | 4,484 | — | — |
Show Business Segments breakouts |
|||
| Agilent CrossLab | 1,171 | — | — |
| Applied Markets | 316 | — | — |
| Life Sciences and Diagnostics Markets | 2,997 | — | — |
| Long Term Investments | 135 | — | — |
| Other Non-Current Assets | 1,075 | — | — |
| Total Assets | 12,813 | — | — |
| Operating Lease Right-of-Use Assets | 189 | 172 | +9.9% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 426 | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 154 | — | — |
| Developed Technology Rights | 239 | — | — |
| Order Or Production Backlog | 7 | — | — |
| Third-Party Technology and Licenses | 10 | — | — |
| Trademarks | 16 | — | — |
| Current Liabilities | |||
| Accounts Payable | 602 | — | — |
| Employee Related Liabilities Current | 297 | — | — |
| Deferred Revenue | 682 | — | — |
| Short Term Borrowings | 304 | — | — |
Show Debt Instrument breakouts |
|||
| Other Loans | 4 | — | — |
| Other Accrued Liabilities Current And Noncurrent | 349 | — | — |
| Total Current Liabilities | 2,234 | — | — |
| Current Portion of Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| Senior Notes 2026 · Senior Notes | 300 | — | — |
| Non-Current Liabilities | |||
| Long-Term Debt | 3,050 | — | — |
Show Debt Instrument breakouts |
|||
| Other Loans | 18 | — | — |
| Senior Notes | 3,032 | — | — |
| Senior Notes 2027 | 597 | — | — |
| Senior Notes 2029 | 497 | — | — |
| Senior Notes 2030 | 498 | — | — |
| Senior Notes 2031 | 846 | — | — |
| Senior Notes 2034 | 594 | — | — |
| Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent | 130 | — | — |
| Other Non-Current Liabilities | 491 | — | — |
| Total Liabilities | 5,905 | — | — |
| Stockholders' Equity | |||
| Common Stock | 3 | — | — |
| Additional Paid-In Capital | 5,605 | — | — |
| Retained Earnings | 1,484 | — | — |
| Accumulated Other Comprehensive Income | -184 | — | — |
| Total Stockholders' Equity | 6,908 | — | — |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -184 | -381 | +51.7% |
| Additional Paid In Capital | 5,605 | 5,489 | +2.1% |
| Common Stock | 3 | 3 | 0.0% |
| Parent | 6,908 | 6,027 | +14.6% |
| Retained Earnings | 1,484 | 916 | +62.0% |
| Total Liabilities & Equity | 12,813 | — | — |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 67 | 72 | -6.9% |
| Stock-Based Compensation | 41 | 40 | +2.5% |
| Deferred Income Taxes | 25 | -10 | +350.0% |
| Other Non-Cash Items | -2 | — | — |
| Change in Accounts Receivable | -18 | -30 | +40.0% |
| Change in Inventory | -39 | -40 | +2.5% |
| Change in Accounts Payable | 39 | 3 | +1200.0% |
| Change in Deferred Revenue | 301 | — | — |
| Net Cash from Operations | 268 | 431 | -37.8% |
| Investing Activities | |||
| Capital Expenditures | -93 | -97 | +4.1% |
| Net Cash from Investing | -93 | -94 | +1.1% |
| Financing Activities | |||
| Share Repurchases | -152 | -90 | -68.9% |
| Tax Withholding for Share Compensation | 27 | 22 | +22.7% |
| Net Cash from Financing | -222 | -180 | -23.3% |
| Supplemental | |||
| Income Taxes Paid | 105 | 19 | +452.6% |
| Interest Paid | 1 | 3 | -66.7% |
| Other Cash Flow | |||
| Net Change in Cash | -31 | 138 | -122.5% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.